You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

Claims for Patent: 10,912,751

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,912,751

Title:	Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Abstract:	Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
Inventor(s):	Newton; Roger Schofield (Ann Arbor, MI), Rosenberg; Noah Laban (Livingston, NJ), MacDougall; Diane Elaine (Lincoln, MA)
Assignee:	Esperion Therapeutics, Inc. (Ann Arbor, MI)
Application Number:	15/558,084
Patent Claims:	1. A method of treating familial hypercholesterolemia in a subject in need thereof, the method comprising administering a fixed-dosed combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe to the subject, wherein the fixed-dose combination comprises a fixed 180 milligram (mg) dose of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and a fixed 10 milligram (mg) dose of Ezetimibe. 2. The method of claim 1, wherein administering the fixed-dose combination decreases the level of LDL-C in the subject below that of a control subject receiving a placebo. 3. The method of claim 1, wherein administering the fixed-dose combination decreases the level of C-reactive protein (hsCRP) in the subject. 4. The method of claim 1, wherein administering the fixed-dose combination decreases the number of very low density lipoprotein in the subject. 5. The method of claim 1, wherein administering the fixed-dose combination reduces the risks of cardiovascular diseases in the subject. 6. The method of claim 1, wherein administering the fixed-dose combination decreases the level of LDL-C in the subject by at least 30% relative to baseline. 7. The method of claim 1, wherein administering the fixed-dose combination decreases the level of hsCRP in the subject by at least 26% relative to baseline. 8. The method of claim 1, wherein administering the fixed-dose combination decreases the level of hsCRP in the subject by at least 30% relative to baseline. 9. The method of claim 1, wherein the fixed-dose combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe is administered once daily to the subject. 10. The method of claim 1, wherein the fixed dose combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe is formulated to be a tablet. 11. The method of claim 1, wherein the fixed dose combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe is formulated for oral delivery. 12. The method of claim 1, wherein the fixed dose combination of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and Ezetimibe is formulated for administration once daily. 13. The method of claim 1, wherein the subject is human.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.